Reported about 17 hours ago
At the JP Morgan 2025 Healthcare Conference, Intuitive Surgical's CEO Gary Guthart discussed the negative impact of GLP-1 receptor agonists on the bariatric surgery market, highlighting a decline in demand for robot-assisted procedures. Despite these challenges, Intuitive Surgical reported a 25% revenue increase in Q4 2024 and maintained a strong market presence, anticipating a 13% to 16% growth in procedure volumes due to a shift in the healthcare landscape influenced by weight loss medications and partnerships with pharmaceutical companies.
Source: YAHOO